Compare Sanofi SA (SNY) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs State Street Technology Select Sector SPDR ETF — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while State Street Technology Select Sector SPDR ETF trades at $198.92 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| SNY | XLK | |
|---|---|---|
Market Cap | $95.18B | $132.55B |
Volume | 2,995,646 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $202.00 |
52-Week Low | $39.51 | $127.49 |
Typical Hold Time | 94 Days | 50 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
XLK trades at $198.68, down 1.35% on the day, with technical indicators showing a bullish overall signal driven by strong moving average support. The ETF maintains neutral oscillators with RSI readings around 60, suggesting balanced momentum. Recent news highlights ongoing investor focus on AI sector dynamics and concentration concerns within XLK's holdings, particularly its heavy chip exposure that may limit diversification benefits despite quarterly rebalancing.
The outlook for XLK remains tied to technology sector performance and AI investment trends, with potential upside from continued enterprise software strength and semiconductor demand. Key risks include interest rate sensitivity, sector concentration, and competitive ETF alternatives offering better risk-adjusted returns. Investors should weigh XLK's cost efficiency against its mega-cap heavy structure when considering technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
